Skip to content

The Effect of Parathyroidectomy on Renal Function, Endothelial Function, and Blood Pressure

Observational Study to Evaluate the Effect of Parathyroidectomy on Renal Function, Endothelial Function and Blood Pressure

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00452049
Enrollment
20
Registered
2007-03-26
Start date
2005-04-30
Completion date
Unknown
Last updated
2012-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperparathyroidism, Hypertension

Keywords

parathyroidectomy, arterial stiffness, renal function

Brief summary

Secondary hyperparathyroidism (HPT) is a known complication of chronic renal failure. Elevated concentrations of parathyroid hormone (PTH) play a role not only in the pathogenesis of renal bone disease, but also in the development of cardiovascular risk factors such as disturbed lipid metabolism, glucose intolerance, and hypertension. HPT is also known to play an important role in the development of structural abnormalities of both large arteries and the heart (left ventricular hypertrophy, interstitial fibrosis). In the last couple of years there has been increasing evidence from animal studies that the endothelium is a target organ of PTH. Hypothesis: PTH has clinically relevant effects on renal hemodynamics, renal function and endothelial function. Aims: 1. To evaluate the effect of parathyroidectomy (PTX) on renal hemodynamics in stable renal transplant recipients 2. To evaluate the effect of PTX on endothelial function in stable renal transplant recipients/chronic kidney disease (CKD) stage 5 patients 3. To evaluate the effect of PTX on blood pressure in stable renal transplant recipients/CKD stage 5 patients

Interventions

PROCEDUREparathyroidectomy

parathyroidectomy

Sponsors

Universitaire Ziekenhuizen KU Leuven
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. Stable renal transplant recipients/CKD stage 5D patients. 2. Age between 18 years and 85 years. 3. Signed informed consent. 4. PTX scheduled because of severe hyperparathyroidism (day 0)

Countries

Belgium

Contacts

Primary ContactPieter Evenepoel, MD, PhD
pieter.evenepoel@uz.kuleuven.ac.be003216344580

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026